UNSPSC 51172708: Butabarbital/hyoscyamine/phenazopyridine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.

UNSPSC 51172708 Butabarbital/hyoscyamine/phenazopyridine is a Commodity code under which state and local governments procure pharmaceutical products and drug-testing services, though the recent opportunities tagged to this code show limited direct relevance to the specific combination drug named. The three posted opportunities reflect broader state and local pharmaceutical and specimen-testing procurement: Collin County Community Supervision and Corrections Department is soliciting offender specimen collection and drug testing services via RFP 2026-327 (response due July 23, 2026, estimated value $600,000 over two years with optional renewals), the Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon (proposals due March 26, 2026). The issuing bodies span state health and human services agencies, county criminal justice departments, and multistate cooperative purchasing vehicles. Drug testing and pharmaceutical supply dominate the recent activity; the Collin County work encompasses staffing collection sites, immunoassay screening with LC/MS/MS or GC/MS confirmation, lab certification from SAMHSA or state authorities, and per-test pricing models with no surcharges permitted.

Recent activity centers on Texas and Minnesota. Collin County's two-year contract (commencing September 1, 2026) covers approximately 25,031 annual tests across five-panel and six-panel screens with alternative methodologies including oral fluid and hair testing; pricing evaluation weighted at 30 percent alongside vendor understanding (30 percent), firm qualifications (25 percent), and client references (15 percent), with optional Phase 2 demonstrations available for up to 30 additional points. The MMCAP RFP requires manufacturers to supply products through AmerisourceBergen, Cardinal Health, and Morris & Dickson; pricing weighted at 75 percent of evaluation, with mandatory cGMP and DSCSA compliance, $2 million network security and privacy liability insurance, and performance penalties of $200–$1,500 per violation. The code shows active state and local procurement in pharmaceutical supply and forensic drug testing, though the specific combination butabarbital/hyoscyamine/phenazopyridine does not appear explicitly in these three opportunities.